Gabriela Pataccini
Overview
Explore the profile of Gabriela Pataccini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pataccini G, Elia A, Sequeira G, Ambrosio L, Coianis M, Lamb C, et al.
Sci Rep
. 2025 Jan;
15(1):2415.
PMID: 39827242
Breast cancer (BC) patient-derived xenografts (PDX) are relevant models for precision medicine. However, there are no collections derived from South American BC patients. Since ethnicity significantly impacts clinical outcomes, it...
2.
Elia A, Pataccini G, Saldain L, Ambrosio L, Lanari C, Rojas P
J Steroid Biochem Mol Biol
. 2024 Mar;
241:106515.
PMID: 38554981
The development of antiprogestins was initially a gynecological purpose. However, since mifepristone was developed, its application for breast cancer treatment was immediately proposed. Later, new compounds with lower antiglucocorticoid and...
3.
Elia A, Saldain L, Vanzulli S, Helguero L, Lamb C, Fabris V, et al.
Clin Cancer Res
. 2022 Oct;
29(5):866-877.
PMID: 36269797
Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast carcinomas that express higher levels of progesterone receptor isoform A (PRA) than isoform B (PRB). Thus, we designed...
4.
Abascal M, Elia A, Alvarez M, Pataccini G, Sequeira G, Riggio M, et al.
Int J Cancer
. 2021 Dec;
150(9):1481-1496.
PMID: 34935137
Progesterone receptors (PRs) ligands are being tested in luminal breast cancer. There are mainly two PR isoforms, PRA and PRB, and their ratio (PRA/PRB) may be predictive of antiprogestin response....
5.
Pataccini G, Pedrozo W, Mathet V, Biglione M, Delfino C
Eur J Gastroenterol Hepatol
. 2021 Aug;
33(9):1229.
PMID: 34397641
No abstract available.
6.
Sequeira G, Sahores A, DAlotto-Moreno T, Perrotta R, Pataccini G, Vanzulli S, et al.
Cancer Res
. 2020 Dec;
81(5):1375-1387.
PMID: 33268529
The role of active antitumor immunity in hormone receptor-positive (HR) breast cancer has been historically underlooked. The aim of this study was to determine the contribution of the immune system...
7.
Pataccini G, Berini C, Pedrozo W, Biglione M, Delfino C
J Med Virol
. 2020 Jul;
93(6):3995-3998.
PMID: 32725912
Human T-lymphotropic virus 1/2 (HTLV-1/2), hepatitis B virus (HBV), and hepatitis D virus (HDV) share transmission routes. Argentina shows low prevalence of HTLV-1/2, HBV, and HDV infections; however, this situation...
8.
Giulianelli S, Riggio M, Guillardoy T, Perez Pinero C, Gorostiaga M, Sequeira G, et al.
Int J Cancer
. 2019 Mar;
145(7):1874-1888.
PMID: 30843188
Progression to hormone-independent growth leading to endocrine therapy resistance occurs in a high proportion of patients with estrogen receptor alpha (ERα) and progesterone receptors (PR) positive breast cancer. We and...
9.
Canepa C, Salido J, Ruggieri M, Fraile S, Pataccini G, Berini C, et al.
Viruses
. 2015 Oct;
7(11):5643-58.
PMID: 26516904
Background: indeterminate Western blot (WB) patterns are a major concern for diagnosis of human T-cell lymphotropic virus type 1 (HTLV-1) infection, even in non-endemic areas. Objectives: (a) to define the...
10.
Delfino C, Gentile E, Castillo A, Cuestas M, Pataccini G, Canepa C, et al.
Arch Virol
. 2013 Dec;
159(5):1109-17.
PMID: 24306325
In Argentina, current procedures to ensure the safety of the blood supply for transfusion include the serologic detection of specific blood-borne infections. The aim of this study was to evaluate...